ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT05217446

Public ClinicalTrials.gov record NCT05217446. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 9:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER

Study identification

NCT ID
NCT05217446
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
107 participants

Conditions and interventions

Interventions

  • Cetuximab Biological
  • Encorafenib Drug
  • Pembrolizumab Biological

Biological · Drug

Eligibility (public fields only)

Age range
16 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 10, 2022
Primary completion
May 31, 2026
Completion
Jan 25, 2027
Last update posted
Apr 6, 2026

2022 – 2027

United States locations

U.S. sites
6
U.S. states
4
U.S. cities
5
Facility City State ZIP Site status
Mayo Clinic Building - Phoenix Phoenix Arizona 85054
Mayo Clinic Hospital Phoenix Arizona 85054
Mayo Clinic Scottsdale Arizona 85259
Mount Sinai Cancer Center Miami Beach Florida 33140
The West Clinic, PLLC dba West Cancer Center Germantown Tennessee 38138
MD Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05217446, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 6, 2026 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05217446 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →